| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
1 company
Gert L. Perlhagen last filed a Form 4 in May 2017, as Director at NVCR. Gert L. Perlhagen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 6,125,000 shares of NVCR. The NVCR filings lean toward selling, a net 551,576 shares.
Gert L. Perlhagen has 4 Form 4 filings on record from August 2016 to May 2017, all as Director at NovoCure (NVCR), 2016–2017.
The 12 reported transactions were 8 open-market sales, 2 other transactions, 1 option or other derivative award and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $866K and 1 sale worth about $1.3M.
The only open-market purchase was 125,000 shares of NVCR at an average $6.93 on March 14, 2017, about $866K.
The only open-market sale was 676,576 shares of NVCR at an average $1.85 on August 5, 2016, about $1.3M.
Shares as reported in the last Form 4 for each company; the most recent is from May 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.